Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 2, 2007, Pages 145-150

  Nielsen, Vance G ^a   Kirklin, James K ^b   Hoogendoorn, Hugh ^c   Ellis, Truitt C ^a   Holman, William L ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Kentucky   (United States)

^c Affinity Biologicals Inc   (Canada)

Author keywords

Coagulation; Factor XIII; Measurement techniques; Thrombelastography

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBOSIS;

ANTIBODIES; BIOMECHANICS; BLOOD COAGULATION; FACTOR XIII; FACTOR XIII DEFICIENCY; HUMANS; KINETICS; THROMBELASTOGRAPHY; THROMBOPHILIA;

EID: 33846930612     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32802f7d91     Document Type: Article

References (14)

1. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005; 46:1820-1826.
2. McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005; 100:1576-1583.
3. Wettstein P, Haeberli A, Stutz M, Rohner M, Corbetta C, Gabi K, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99:1564-1569.
4. Nielsen VG. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions. Acta Anaesth Scand 2005; 49:1163-1171.
5. Parry DJ, Grant PJ, Scott DJA. Atherothrombotic risk factor clusting in healthy male relatives of male patients with intermittent claudication. J Vasc Surg 2004; 40:891-898.
6. Ames PRJ, Iannaccone L, Alves JD, Margarita A, Lopez LR, Brancaccio V. Factor XIII in primary antiphospholipid syndrome. J Rheumatol 2005; 32:1058-1062.
7. Schroeder V, Chatterjee T, Kohler H. Influence of blood coagulation FXIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001; 104:467-474.
8. Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased Factor XIII activity: implications of a prospective study. Stroke 2002; 33:1618-1623.
9. Greilich PE, Alving BM, O'Neill KL, Chang AS, Reid TJ. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Anesth Analg 1997; 84:31-38.
10. Nielsen VG, Gurley WG, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg 2004; 99:120-123.
11. Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK. Argatroban, bivalirudin and lepirudin do not decrease clot propagation and strength as effectively as heparin activated antithrombin in vitro. J Heart Lung Transplant 2006; 25:653-663.
12. Greenberg CS, Shuman MA. The zymogen form of blood coagulation factor XIII binds specifically to fibrinogen. J Biol Chem 1982; 257:6096-6101.
13. Greenberg CS, Dobson JV, Miraglia CC. Regulation of plasma factor XIII binding to fibrin in vitro. Blood 1985; 66:1028-1034.
14. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin activatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 2006; 25:1247-1252.